Table 2:

Association between AGA and progression free survival in EBRT+BT-treated patients

		AGA+Stage (Stage 2+3, BT)			Stage 2, BT			Stage 3, BT
Group	Gly #	HR (95% CI)	P-val	Pc	HR (95% CI)	P-val	Pc	HR (95% CI)	P-val	Pc
Blood Group H	122	0.66(0.52 – 0.84)	0.0009	0.005	0.7(0.45 – 1.09)	0.117		0.59(0.4 – 0.86)	0.0067	0.040
	123	0.73(0.56 – 0.96)	0.0218		0.8(0.5 – 1.29)	0.357		0.62(0.4 – 0.95)	0.0269
	124	0.69(0.55 – 0.88)	0.0024	0.014	0.59(0.38 – 0.9)	0.016	0.093	0.59(0.4 – 0.86)	0.0057	0.034
Ganglio-series	164	0.81(0.63 – 1.04)	0.0989		0.86(0.55 – 1.33)	0.492		0.59(0.39 – 0.89)	0.0128
	168	0.84(0.66 – 1.07)	0.1591		0.78(0.5 – 1.2)	0.257		0.72(0.5 – 1.06)	0.0970
Isoglobo-series	153	0.71(0.55 – 0.91)	0.0067	0.040	0.71(0.45 – 1.12)	0.138		0.61(0.41 – 0.89)	0.0113
	154	0.74(0.56 – 0.96)	0.0228		0.59(0.37 – 0.92)	0.021	0.126	0.66(0.44 – 1)	0.0524
	155	0.79(0.62 – 1)	0.0513		0.72(0.47 – 1.11)	0.141		0.7(0.48 – 1.02)	0.0669
	156	0.9(0.71 – 1.14)	0.3835		0.79(0.52 – 1.22)	0.291		0.8(0.55 – 1.17)	0.2546
	192	1.09(0.86 – 1.39)	0.4630		1.01(0.66 – 1.56)	0.948		1(0.68 – 1.46)	0.9936
Lewis antigens	128	0.72(0.57 – 0.92)	0.0078	0.047	0.72(0.47 – 1.1)	0.126		0.67(0.46 – 0.98)	0.0368
	129	0.75(0.59 – 0.95)	0.0173		0.65(0.42 – 0.99)	0.045	0.269	0.74(0.51 – 1.08)	0.1178
	133	0.78(0.6 – 1.01)	0.0592		0.78(0.48 – 1.26)	0.304		0.67(0.44 – 1.01)	0.0574
	136	0.72(0.56 – 0.92)	0.0095	0.057	0.82(0.52 – 1.27)	0.373		0.49(0.32 – 0.74)	0.0008	0.005
	137	0.78(0.61 – 1)	0.0522		0.83(0.54 – 1.28)	0.402		0.61(0.41 – 0.91)	0.0162
	138	0.74(0.58 – 0.94)	0.0154		0.71(0.46 – 1.11)	0.138		0.64(0.43 – 0.95)	0.0254
	139	0.79(0.62 – 1)	0.0471		0.72(0.47 – 1.1)	0.126		0.66(0.45 – 0.96)	0.0297
Lacto-series	140	0.75(0.59 – 0.96)	0.0246		0.61(0.39 – 0.96)	0.033	0.200	0.67(0.45 – 1)	0.0473
	143	0.74(0.57 – 0.95)	0.0185		0.84(0.54 – 1.31)	0.438		0.56(0.37 – 0.84)	0.0056	0.034
Sialylated Tetraose	160	0.76(0.59 – 0.97)	0.0277		0.91(0.59 – 1.41)	0.666		0.54(0.35 – 0.81)	0.0030	0.018

P-val: P- value, Pc: 137,corrected p-values,